AI
Only 1M dilution to repay debt. That is 3.8% of the current o/s (fully diluted). The other shares that are being offered are a conversion of already outstanding shares.
Pace acquisition adds 5M to bottom line, or at least +12.5%, when compared to current EBITDA.
The acquisition has a slight impact on 2019 costs and thus LE, therefore the 5 cents lower EPS expectation 2019.
A crucial strategic move for IIIV. Shareprice will recover nicely once investors see the value of this strategic move
PS: it is already ticking up again.
I added @ 22.83
Recent IIIV News
FEATURED Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • Jul 8, 2025 8:30 AM
Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America • AVAI • Jul 8, 2025 8:00 AM
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • CLDI • Jul 7, 2025 9:00 AM
VAYK Discloses More Insider Buying Approaching 15 Million • VAYK • Jul 2, 2025 10:37 AM
Patented, Groundbreaking Blockchain for Public Companies 'BlackStar Digital Trading PlatformTM' can Facilitate U.S. Registered Securities to Trade on Blockchain Without Tokens. • BEGI • Jul 1, 2025 12:54 PM
UC Asset (UCASU) Public Offering's Acquisition Target Reported Better Results • UCASU • Jul 1, 2025 9:15 AM
